Rigel Pharmaceuticals (RIGL) Raw materials — Quarterly & Annual

Screener

Raw materials at other companies

AmgenAMGN

$1.08B+22.3%

Agios PharmaceuticalsAGIO

$374K+320%

Zevra Therapeutics, Inc.ZVRA

$15K-28.6%

Mirum Pharmaceuticals, Inc.MIRM

$2.61M-10.6%

Cumberland PharmaceuticalsCPIX

$9.68M-6.7%

Neurocrine BiosciencesNBIX

$30.7M-3.8%

Other financials

Income statement

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Balance sheet

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Cash flow

Operating cash flow$2.7M+405%

CapEx$73.0K—

Free cash flow-$22.0M—

Valuation

Market cap$750.37M+25.0%

Enterprise value$794.27M+44.9%

P/E2.1×-4.1×

P/S2.5×+0.3×

Profitability

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

FCF margin-61.7%—

Returns & leverage

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterials.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed: May 5, 2026, 4:05 PM EDT
Fiscal quarter: Q4 FY2026
Calendar quarter: Q4 2026
Accession: 0001034842-26-000032

Line item	As of / March 31, 2026	As of / December 31, 2025
Raw materials	$3,427	$4,514
Work in process	6,229	3,910
Finished goods	4,097	4,712
Total	$13,753	$13,136
Reported as:
Inventories	$11,652	$11,506
Other assets	2,101	1,630
Total	$13,753	$13,136

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's raw materials?: Rigel Pharmaceuticals (RIGL) reported raw materials of $3.43M in Q1 2026.
What does raw materials mean?: Unprocessed materials and components purchased for use in manufacturing, valued at cost.

Ask your AI about Rigel Pharmaceuticals's raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk